Corporate Contact: Kevin MoranSenior Vice President, Chief Financial Officer and TreasurerVanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com Elizabeth Van Every Head of Corporate Affairs Vanda ...
Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Vanda Pharmaceuticals Inc. Earnings Conference Call. I would now like to turn the call over to Kevin Moran, Vanda's Chief ...
WASHINGTON, June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New ...
WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November ...
WASHINGTON, Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, ...
D.C.-based Vanda Pharmaceuticals has completed early stage clinical trials for an experimental treatment for acute performance anxiety in social situations, such as public speaking. The Phase II ...
--Vanda Pharmaceuticals Inc. today announced financial and operational results for the fourth quarter and full year ended December 31, 2022. Total net product sales from HETLIOZ ® and Fanapt ® were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results